A phase I/II clinical trial investigating linsitinib, another dual IR/IGF-1R inhibitor, in combination with the chemotherapy drug paclitaxel found that, compared with paclitaxel alone, adding intermittent or continuous linsitinib treatment did not improve overall survival, response rate, or disease control rate in platinum-resistant ovarian cancer [51]. The gene discussed is INSR; the disease is ovarian carcinoma.